RGT-075 is under clinical development by Qilu Regor Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RGT-075’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RGT-075 is under development for the treatment of type 2 diabetes. It acts by targeting glucagon like peptide 1 receptor (GLP1R). It is administered through oral route. The drug candidate is being developed based on CARD (Computer Accelerated Rational Discovery) platform.
Qilu Regor Therapeutics overview
Regor Pharmaceuticals Inc (Regor) is a biotechnology company that discovers and develops medicines for the treatment of cancer, immune disorders and metabolic diseases. Regor is headquartered in Boston, Massachusetts, the US.
For a complete picture of RGT-075’s drug-specific PTSR and LoA scores, buy the report here.